BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

Patient-Reported Efficacy of Subcutaneous (SC) Abatacept in Rheumatoid Arthritis (RA) - South Africa

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Abatacept

First Posted Date: 2015-11-06

Last Posted Date: 2016-02-08

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 69

Registration Number: NCT02598466

An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma

Phase 4

Completed

Conditions: Renal Cell Carcinoma

Interventions: Drug: Nivolumab

First Posted Date: 2015-11-04

Last Posted Date: 2022-10-27

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 197

Registration Number: NCT02596035

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore, Maryland, United States
🇺🇸
Local Institution - 0039, Seattle, Washington, United States
🇺🇸
Baptist Health Medical Group Oncology, Miami, Florida, United States

and more 36 locations

A Study of Safety, Tolerability and Pharmacokinetics of Nivolumab in Chinese Subjects With Previously Treated Advanced or Recurrent Solid Tumors

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: Nivolumab

First Posted Date: 2015-11-01

Last Posted Date: 2022-10-24

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 58

Registration Number: NCT02593786

Locations: 🇨🇳
Local Institution - 0001, Guangzhou, Guangdong, China
🇨🇳
Local Institution, Hangzhou, Zhejiang, China

A Nationwide Registry Study of Patients With Nonvalvular Atrial Fibrillation Initiating Oral Anticoagulation Therapies In The Early Period Following Apixaban Marketing In Denmark

Completed

Conditions: Anticoagulation

First Posted Date: 2015-10-30

Last Posted Date: 2016-05-18

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 52178

Registration Number: NCT02591732

Locations: 🇩🇰
Local Institution, Hellerup, Denmark

Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)

Phase 2

Completed

Conditions: Nephrotic Syndrome
Focal Segmental Glomerulosclerosis
Minimal Change Disease

Interventions: Other: Normal Saline
Drug: Abatacept
Other: D5W

First Posted Date: 2015-10-30

Last Posted Date: 2021-03-05

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 36

Registration Number: NCT02592798

Locations: 🇺🇸
Levine Children's Hospital, Charlotte, North Carolina, United States
🇺🇸
Children's National Health System, Washington, District of Columbia, United States
🇺🇸
Columbia University Medical Center (Cumc), New York, New York, United States

and more 24 locations

A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Phase 2

Withdrawn

Conditions: Scleroderma

Interventions: Drug: BMS-986020
Other: Placebo

First Posted Date: 2015-10-28

Last Posted Date: 2016-07-22

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT02588625

Locations: 🇬🇧
Local Institution, London, Greater London, United Kingdom

An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas

Phase 1

Completed

Conditions: Non-Hodgkin's Disease

Interventions: Biological: Nivolumab
Drug: Brentuximab Vedotin

First Posted Date: 2015-10-21

Last Posted Date: 2023-03-07

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 145

Registration Number: NCT02581631

Locations: 🇺🇸
Winship Cancer Institute., Atlanta, Georgia, United States
🇺🇸
University Of Chicago, Chicago, Illinois, United States
🇺🇸
Local Institution - 0003, New York, New York, United States

and more 24 locations

Assessment of Effectiveness of Belatacept Patient Alert Card in Patients Following Renal Transplantation in a Sample of EU Countries

Completed

Conditions: Renal Transplant

First Posted Date: 2015-10-21

Last Posted Date: 2017-06-16

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 63

Registration Number: NCT02581644

Locations: 🇫🇷
CHU Clemont Ferrand, Clermont-Ferrand, France
🇫🇷
APHP Hopital Henri Mondor, Créteil, France
🇸🇪
Local Institution, Uppsala, Sweden

and more 5 locations

An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma

Phase 3

Completed

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Sorafenib
Drug: Nivolumab

First Posted Date: 2015-10-15

Last Posted Date: 2024-03-19

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 743

Registration Number: NCT02576509

Locations: 🇮🇹
Local Institution - 0055, Milan, Italy
🇦🇹
Local Institution - 0039, Graz, Austria
🇧🇪
Local Institution - 0075, Bruxelles, Belgium

and more 135 locations

Safety, Pharmacokinetics and Pharmacodynamics of BMS-936559 in Severe Sepsis

Phase 1

Terminated

Conditions: Severe Sepsis
Septic Shock

Interventions: Other: Placebo
Biological: BMS-936559

First Posted Date: 2015-10-15

Last Posted Date: 2017-09-15

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 35

Registration Number: NCT02576457

Locations: 🇺🇸
Uc Davis Medical Center, Sacramento, California, United States
🇺🇸
Local Institution, Seattle, Washington, United States
🇺🇸
Emory University, Atlanta, Georgia, United States

and more 9 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy